Rotavirus Infections Drug Industry Research Report 2025
Description
Summary
According to APO Research, the global Rotavirus Infections Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Rotavirus Infections Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Rotavirus Infections Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Rotavirus Infections Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Rotavirus Infections Drug include Wuhan Institute of Biological Products Co Ltd, Beijing Minhai Biotechnology Co Ltd, UMN Pharma Inc, Serum Institute of India Ltd, Nanotherapeutics Inc, Medicago Inc, Curevac AG, Biological E Ltd and Bharat Biotech International Ltd, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Rotavirus Infections Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rotavirus Infections Drug.
The report will help the Rotavirus Infections Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Rotavirus Infections Drug market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Rotavirus Infections Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Rotavirus Infections Drug Segment by Company
Wuhan Institute of Biological Products Co Ltd Beijing Minhai Biotechnology Co Ltd UMN Pharma Inc Serum Institute of India Ltd Nanotherapeutics Inc Medicago Inc Curevac AG Biological E Ltd Bharat Biotech International LtdRotavirus Infections Drug Segment by Type
UMN-2001 RV-625 RV-3BB Rotavac-5C OthersRotavirus Infections Drug Segment by Application
Clinic Hospital OthersRotavirus Infections Drug Segment by Region
North America United States Canada Europe Germany France U.K. Italy Netherlands Nordic Countries Asia-Pacific China Japan South Korea India Australia China Taiwan Southeast Asia South America Mexico Brazil Argentina Middle East & Africa Turkey Saudi Arabia UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rotavirus Infections Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rotavirus Infections Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rotavirus Infections Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Rotavirus Infections Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Rotavirus Infections Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Rotavirus Infections Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
According to APO Research, the global Rotavirus Infections Drug market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Rotavirus Infections Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Rotavirus Infections Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Rotavirus Infections Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Rotavirus Infections Drug include Wuhan Institute of Biological Products Co Ltd, Beijing Minhai Biotechnology Co Ltd, UMN Pharma Inc, Serum Institute of India Ltd, Nanotherapeutics Inc, Medicago Inc, Curevac AG, Biological E Ltd and Bharat Biotech International Ltd, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Rotavirus Infections Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rotavirus Infections Drug.
The report will help the Rotavirus Infections Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
The Rotavirus Infections Drug market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Rotavirus Infections Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Rotavirus Infections Drug Segment by Company
Wuhan Institute of Biological Products Co Ltd Beijing Minhai Biotechnology Co Ltd UMN Pharma Inc Serum Institute of India Ltd Nanotherapeutics Inc Medicago Inc Curevac AG Biological E Ltd Bharat Biotech International LtdRotavirus Infections Drug Segment by Type
UMN-2001 RV-625 RV-3BB Rotavac-5C OthersRotavirus Infections Drug Segment by Application
Clinic Hospital OthersRotavirus Infections Drug Segment by Region
North America United States Canada Europe Germany France U.K. Italy Netherlands Nordic Countries Asia-Pacific China Japan South Korea India Australia China Taiwan Southeast Asia South America Mexico Brazil Argentina Middle East & Africa Turkey Saudi Arabia UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rotavirus Infections Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rotavirus Infections Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rotavirus Infections Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Rotavirus Infections Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Rotavirus Infections Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Rotavirus Infections Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
Table of Contents
120 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Rotavirus Infections Drug Market Size (2020-2031)
- 2.2.2 Global Rotavirus Infections Drug Sales (2020-2031)
- 2.2.3 Global Rotavirus Infections Drug Market Average Price (2020-2031)
- 2.3 Rotavirus Infections Drug by Type
- 2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- 2.3.2 UMN-2001
- 2.3.3 RV-625
- 2.3.4 RV-3BB
- 2.3.5 Rotavac-5C
- 2.3.6 Others
- 2.4 Rotavirus Infections Drug by Application
- 2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.4.2 Clinic
- 2.4.3 Hospital
- 2.4.4 Others
- 3 Market Competitive Landscape by Manufacturers
- 3.1 Global Rotavirus Infections Drug Market Competitive Situation by Manufacturers (2020 Versus 2024)
- 3.2 Global Rotavirus Infections Drug Sales (k units) of Manufacturers (2020-2025)
- 3.3 Global Rotavirus Infections Drug Revenue of Manufacturers (2020-2025)
- 3.4 Global Rotavirus Infections Drug Average Price by Manufacturers (2020-2025)
- 3.5 Global Rotavirus Infections Drug Industry Ranking, 2023 VS 2024 VS 2025
- 3.6 Global Manufacturers of Rotavirus Infections Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Rotavirus Infections Drug, Product Type & Application
- 3.8 Global Manufacturers of Rotavirus Infections Drug, Established Date
- 3.9 Global Rotavirus Infections Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
- 4 Manufacturers Profiled
- 4.1 Wuhan Institute of Biological Products Co Ltd
- 4.1.1 Wuhan Institute of Biological Products Co Ltd Company Information
- 4.1.2 Wuhan Institute of Biological Products Co Ltd Business Overview
- 4.1.3 Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.1.4 Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Product Portfolio
- 4.1.5 Wuhan Institute of Biological Products Co Ltd Recent Developments
- 4.2 Beijing Minhai Biotechnology Co Ltd
- 4.2.1 Beijing Minhai Biotechnology Co Ltd Company Information
- 4.2.2 Beijing Minhai Biotechnology Co Ltd Business Overview
- 4.2.3 Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.2.4 Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Product Portfolio
- 4.2.5 Beijing Minhai Biotechnology Co Ltd Recent Developments
- 4.3 UMN Pharma Inc
- 4.3.1 UMN Pharma Inc Company Information
- 4.3.2 UMN Pharma Inc Business Overview
- 4.3.3 UMN Pharma Inc Rotavirus Infections Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.3.4 UMN Pharma Inc Rotavirus Infections Drug Product Portfolio
- 4.3.5 UMN Pharma Inc Recent Developments
- 4.4 Serum Institute of India Ltd
- 4.4.1 Serum Institute of India Ltd Company Information
- 4.4.2 Serum Institute of India Ltd Business Overview
- 4.4.3 Serum Institute of India Ltd Rotavirus Infections Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.4.4 Serum Institute of India Ltd Rotavirus Infections Drug Product Portfolio
- 4.4.5 Serum Institute of India Ltd Recent Developments
- 4.5 Nanotherapeutics Inc
- 4.5.1 Nanotherapeutics Inc Company Information
- 4.5.2 Nanotherapeutics Inc Business Overview
- 4.5.3 Nanotherapeutics Inc Rotavirus Infections Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.5.4 Nanotherapeutics Inc Rotavirus Infections Drug Product Portfolio
- 4.5.5 Nanotherapeutics Inc Recent Developments
- 4.6 Medicago Inc
- 4.6.1 Medicago Inc Company Information
- 4.6.2 Medicago Inc Business Overview
- 4.6.3 Medicago Inc Rotavirus Infections Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.6.4 Medicago Inc Rotavirus Infections Drug Product Portfolio
- 4.6.5 Medicago Inc Recent Developments
- 4.7 Curevac AG
- 4.7.1 Curevac AG Company Information
- 4.7.2 Curevac AG Business Overview
- 4.7.3 Curevac AG Rotavirus Infections Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.7.4 Curevac AG Rotavirus Infections Drug Product Portfolio
- 4.7.5 Curevac AG Recent Developments
- 4.8 Biological E Ltd
- 4.8.1 Biological E Ltd Company Information
- 4.8.2 Biological E Ltd Business Overview
- 4.8.3 Biological E Ltd Rotavirus Infections Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.8.4 Biological E Ltd Rotavirus Infections Drug Product Portfolio
- 4.8.5 Biological E Ltd Recent Developments
- 4.9 Bharat Biotech International Ltd
- 4.9.1 Bharat Biotech International Ltd Company Information
- 4.9.2 Bharat Biotech International Ltd Business Overview
- 4.9.3 Bharat Biotech International Ltd Rotavirus Infections Drug Sales, Revenue and Gross Margin (2020-2025)
- 4.9.4 Bharat Biotech International Ltd Rotavirus Infections Drug Product Portfolio
- 4.9.5 Bharat Biotech International Ltd Recent Developments
- 5 Global Rotavirus Infections Drug Market Scenario by Region
- 5.1 Global Rotavirus Infections Drug Market Size by Region: 2020 VS 2024 VS 2031
- 5.2 Global Rotavirus Infections Drug Sales by Region: 2020-2031
- 5.2.1 Global Rotavirus Infections Drug Sales by Region: 2020-2025
- 5.2.2 Global Rotavirus Infections Drug Sales by Region: 2026-2031
- 5.3 Global Rotavirus Infections Drug Revenue by Region: 2020-2031
- 5.3.1 Global Rotavirus Infections Drug Revenue by Region: 2020-2025
- 5.3.2 Global Rotavirus Infections Drug Revenue by Region: 2026-2031
- 5.4 North America Rotavirus Infections Drug Market Facts & Figures by Country
- 5.4.1 North America Rotavirus Infections Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.4.2 North America Rotavirus Infections Drug Sales by Country (2020-2031)
- 5.4.3 North America Rotavirus Infections Drug Revenue by Country (2020-2031)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Rotavirus Infections Drug Market Facts & Figures by Country
- 5.5.1 Europe Rotavirus Infections Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.5.2 Europe Rotavirus Infections Drug Sales by Country (2020-2031)
- 5.5.3 Europe Rotavirus Infections Drug Revenue by Country (2020-2031)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Rotavirus Infections Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Rotavirus Infections Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.6.2 Asia Pacific Rotavirus Infections Drug Sales by Country (2020-2031)
- 5.6.3 Asia Pacific Rotavirus Infections Drug Revenue by Country (2020-2031)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Rotavirus Infections Drug Market Facts & Figures by Country
- 5.7.1 South America Rotavirus Infections Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.7.2 South America Rotavirus Infections Drug Sales by Country (2020-2031)
- 5.7.3 South America Rotavirus Infections Drug Revenue by Country (2020-2031)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Rotavirus Infections Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Rotavirus Infections Drug Market Size by Country: 2020 VS 2024 VS 2031
- 5.8.2 Middle East and Africa Rotavirus Infections Drug Sales by Country (2020-2031)
- 5.8.3 Middle East and Africa Rotavirus Infections Drug Revenue by Country (2020-2031)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
- 6 Segment by Type
- 6.1 Global Rotavirus Infections Drug Sales by Type (2020-2031)
- 6.1.1 Global Rotavirus Infections Drug Sales by Type (2020-2031) & (k units)
- 6.1.2 Global Rotavirus Infections Drug Sales Market Share by Type (2020-2031)
- 6.2 Global Rotavirus Infections Drug Revenue by Type (2020-2031)
- 6.2.1 Global Rotavirus Infections Drug Sales by Type (2020-2031) & (US$ Million)
- 6.2.2 Global Rotavirus Infections Drug Revenue Market Share by Type (2020-2031)
- 6.3 Global Rotavirus Infections Drug Price by Type (2020-2031)
- 7 Segment by Application
- 7.1 Global Rotavirus Infections Drug Sales by Application (2020-2031)
- 7.1.1 Global Rotavirus Infections Drug Sales by Application (2020-2031) & (k units)
- 7.1.2 Global Rotavirus Infections Drug Sales Market Share by Application (2020-2031)
- 7.2 Global Rotavirus Infections Drug Revenue by Application (2020-2031)
- 7.2.1 Global Rotavirus Infections Drug Sales by Application (2020-2031) & (US$ Million)
- 7.2.2 Global Rotavirus Infections Drug Revenue Market Share by Application (2020-2031)
- 7.3 Global Rotavirus Infections Drug Price by Application (2020-2031)
- 8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Rotavirus Infections Drug Value Chain Analysis
- 8.1.1 Rotavirus Infections Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Rotavirus Infections Drug Production Mode & Process
- 8.2 Rotavirus Infections Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Rotavirus Infections Drug Distributors
- 8.2.3 Rotavirus Infections Drug Customers
- 9 Global Rotavirus Infections Drug Analyzing Market Dynamics
- 9.1 Rotavirus Infections Drug Industry Trends
- 9.2 Rotavirus Infections Drug Industry Drivers
- 9.3 Rotavirus Infections Drug Industry Opportunities and Challenges
- 9.4 Rotavirus Infections Drug Industry Restraints
- 10 Report Conclusion
- 11 Disclaimer
- List of Tables
- Table 1. Secondary Sources
- Table 2. Primary Sources
- Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Table 5. Global Rotavirus Infections Drug Volume and Revenue Market Size and CAGR of Manufacturers (2020 Versus 2024)
- Table 6. Global Rotavirus Infections Drug Sales (k units) of Manufacturers (2020-2025)
- Table 7. Global Rotavirus Infections Drug Sales Market Share by Manufacturers (2020-2025)
- Table 8. Global Rotavirus Infections Drug Revenue of Manufacturers (2020-2025)
- Table 9. Global Rotavirus Infections Drug Revenue Share by Manufacturers (2020-2025)
- Table 10. Global Market Rotavirus Infections Drug Average Price (US$/unit) of Manufacturers (2020-2025)
- Table 11. Global Rotavirus Infections Drug Industry Ranking, 2023 VS 2024 VS 2025
- Table 12. Global Manufacturers of Rotavirus Infections Drug, Manufacturing Sites & Headquarters
- Table 13. Global Manufacturers of Rotavirus Infections Drug, Product Type & Application
- Table 14. Global Rotavirus Infections Drug Manufacturers Established Date
- Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16. Global Rotavirus Infections Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
- Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18. Wuhan Institute of Biological Products Co Ltd Company Information
- Table 19. Wuhan Institute of Biological Products Co Ltd Business Overview
- Table 20. Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 21. Wuhan Institute of Biological Products Co Ltd Rotavirus Infections Drug Product Portfolio
- Table 22. Wuhan Institute of Biological Products Co Ltd Recent Developments
- Table 23. Beijing Minhai Biotechnology Co Ltd Company Information
- Table 24. Beijing Minhai Biotechnology Co Ltd Business Overview
- Table 25. Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 26. Beijing Minhai Biotechnology Co Ltd Rotavirus Infections Drug Product Portfolio
- Table 27. Beijing Minhai Biotechnology Co Ltd Recent Developments
- Table 28. UMN Pharma Inc Company Information
- Table 29. UMN Pharma Inc Business Overview
- Table 30. UMN Pharma Inc Rotavirus Infections Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 31. UMN Pharma Inc Rotavirus Infections Drug Product Portfolio
- Table 32. UMN Pharma Inc Recent Developments
- Table 33. Serum Institute of India Ltd Company Information
- Table 34. Serum Institute of India Ltd Business Overview
- Table 35. Serum Institute of India Ltd Rotavirus Infections Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 36. Serum Institute of India Ltd Rotavirus Infections Drug Product Portfolio
- Table 37. Serum Institute of India Ltd Recent Developments
- Table 38. Nanotherapeutics Inc Company Information
- Table 39. Nanotherapeutics Inc Business Overview
- Table 40. Nanotherapeutics Inc Rotavirus Infections Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 41. Nanotherapeutics Inc Rotavirus Infections Drug Product Portfolio
- Table 42. Nanotherapeutics Inc Recent Developments
- Table 43. Medicago Inc Company Information
- Table 44. Medicago Inc Business Overview
- Table 45. Medicago Inc Rotavirus Infections Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 46. Medicago Inc Rotavirus Infections Drug Product Portfolio
- Table 47. Medicago Inc Recent Developments
- Table 48. Curevac AG Company Information
- Table 49. Curevac AG Business Overview
- Table 50. Curevac AG Rotavirus Infections Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 51. Curevac AG Rotavirus Infections Drug Product Portfolio
- Table 52. Curevac AG Recent Developments
- Table 53. Biological E Ltd Company Information
- Table 54. Biological E Ltd Business Overview
- Table 55. Biological E Ltd Rotavirus Infections Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 56. Biological E Ltd Rotavirus Infections Drug Product Portfolio
- Table 57. Biological E Ltd Recent Developments
- Table 58. Bharat Biotech International Ltd Company Information
- Table 59. Bharat Biotech International Ltd Business Overview
- Table 60. Bharat Biotech International Ltd Rotavirus Infections Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2020-2025)
- Table 61. Bharat Biotech International Ltd Rotavirus Infections Drug Product Portfolio
- Table 62. Bharat Biotech International Ltd Recent Developments
- Table 63. Global Rotavirus Infections Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Table 64. Global Rotavirus Infections Drug Sales by Region (2020-2025) & (k units)
- Table 65. Global Rotavirus Infections Drug Sales Market Share by Region (2020-2025)
- Table 66. Global Rotavirus Infections Drug Sales by Region (2026-2031) & (k units)
- Table 67. Global Rotavirus Infections Drug Sales Market Share by Region (2026-2031)
- Table 68. Global Rotavirus Infections Drug Revenue by Region (2020-2025) & (US$ Million)
- Table 69. Global Rotavirus Infections Drug Revenue Market Share by Region (2020-2025)
- Table 70. Global Rotavirus Infections Drug Revenue by Region (2026-2031) & (US$ Million)
- Table 71. Global Rotavirus Infections Drug Revenue Market Share by Region (2026-2031)
- Table 72. North America Rotavirus Infections Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 73. North America Rotavirus Infections Drug Sales by Country (2020-2025) & (k units)
- Table 74. North America Rotavirus Infections Drug Sales by Country (2026-2031) & (k units)
- Table 75. North America Rotavirus Infections Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 76. North America Rotavirus Infections Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 77. Europe Rotavirus Infections Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 78. Europe Rotavirus Infections Drug Sales by Country (2020-2025) & (k units)
- Table 79. Europe Rotavirus Infections Drug Sales by Country (2026-2031) & (k units)
- Table 80. Europe Rotavirus Infections Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 81. Europe Rotavirus Infections Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 82. Asia Pacific Rotavirus Infections Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 83. Asia Pacific Rotavirus Infections Drug Sales by Country (2020-2025) & (k units)
- Table 84. Asia Pacific Rotavirus Infections Drug Sales by Country (2026-2031) & (k units)
- Table 85. Asia Pacific Rotavirus Infections Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 86. Asia Pacific Rotavirus Infections Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 87. South America Rotavirus Infections Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 88. South America Rotavirus Infections Drug Sales by Country (2020-2025) & (k units)
- Table 89. South America Rotavirus Infections Drug Sales by Country (2026-2031) & (k units)
- Table 90. South America Rotavirus Infections Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 91. South America Rotavirus Infections Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 92. Middle East and Africa Rotavirus Infections Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
- Table 93. Middle East and Africa Rotavirus Infections Drug Sales by Country (2020-2025) & (k units)
- Table 94. Middle East and Africa Rotavirus Infections Drug Sales by Country (2026-2031) & (k units)
- Table 95. Middle East and Africa Rotavirus Infections Drug Revenue by Country (2020-2025) & (US$ Million)
- Table 96. Middle East and Africa Rotavirus Infections Drug Revenue by Country (2026-2031) & (US$ Million)
- Table 97. Global Rotavirus Infections Drug Sales by Type (2020-2025) & (k units)
- Table 98. Global Rotavirus Infections Drug Sales by Type (2026-2031) & (k units)
- Table 99. Global Rotavirus Infections Drug Sales Market Share by Type (2020-2025)
- Table 100. Global Rotavirus Infections Drug Sales Market Share by Type (2026-2031)
- Table 101. Global Rotavirus Infections Drug Revenue by Type (2020-2025) & (US$ Million)
- Table 102. Global Rotavirus Infections Drug Revenue by Type (2026-2031) & (US$ Million)
- Table 103. Global Rotavirus Infections Drug Revenue Market Share by Type (2020-2025)
- Table 104. Global Rotavirus Infections Drug Revenue Market Share by Type (2026-2031)
- Table 105. Global Rotavirus Infections Drug Price by Type (2020-2025) & (US$/unit)
- Table 106. Global Rotavirus Infections Drug Price by Type (2026-2031) & (US$/unit)
- Table 107. Global Rotavirus Infections Drug Sales by Application (2020-2025) & (k units)
- Table 108. Global Rotavirus Infections Drug Sales by Application (2026-2031) & (k units)
- Table 109. Global Rotavirus Infections Drug Sales Market Share by Application (2020-2025)
- Table 110. Global Rotavirus Infections Drug Sales Market Share by Application (2026-2031)
- Table 111. Global Rotavirus Infections Drug Revenue by Application (2020-2025) & (US$ Million)
- Table 112. Global Rotavirus Infections Drug Revenue by Application (2026-2031) & (US$ Million)
- Table 113. Global Rotavirus Infections Drug Revenue Market Share by Application (2020-2025)
- Table 114. Global Rotavirus Infections Drug Revenue Market Share by Application (2026-2031)
- Table 115. Global Rotavirus Infections Drug Price by Application (2020-2025) & (US$/unit)
- Table 116. Global Rotavirus Infections Drug Price by Application (2026-2031) & (US$/unit)
- Table 117. Key Raw Materials
- Table 118. Raw Materials Key Suppliers
- Table 119. Rotavirus Infections Drug Distributors List
- Table 120. Rotavirus Infections Drug Customers List
- Table 121. Rotavirus Infections Drug Industry Trends
- Table 122. Rotavirus Infections Drug Industry Drivers
- Table 123. Rotavirus Infections Drug Industry Restraints
- Table 124. Authors List of This Report
- List of Figures
- Figure 1. Research Methodology
- Figure 2. Research Process
- Figure 3. Key Executives Interviewed
- Figure 4. Rotavirus Infections Drug Product Image
- Figure 5. Global Rotavirus Infections Drug Revenue (US$ Million), 2020 VS 2024 VS 2031
- Figure 6. Global Rotavirus Infections Drug Market Size (2020-2031) & (US$ Million)
- Figure 7. Global Rotavirus Infections Drug Sales (2020-2031) & (k units)
- Figure 8. Global Rotavirus Infections Drug Average Price (US$/unit) & (2020-2031)
- Figure 9. UMN-2001 Product Image
- Figure 10. RV-625 Product Image
- Figure 11. RV-3BB Product Image
- Figure 12. Rotavac-5C Product Image
- Figure 13. Others Product Image
- Figure 14. Clinic Product Image
- Figure 15. Hospital Product Image
- Figure 16. Others Product Image
- Figure 17. Global Rotavirus Infections Drug Revenue Share by Manufacturers in 2024
- Figure 18. Global Manufacturers of Rotavirus Infections Drug, Manufacturing Sites & Headquarters
- Figure 19. Global Top 5 and 10 Rotavirus Infections Drug Players Market Share by Revenue in 2024
- Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 21. Global Rotavirus Infections Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
- Figure 22. Global Rotavirus Infections Drug Sales by Region in 2024
- Figure 23. Global Rotavirus Infections Drug Revenue by Region in 2024
- Figure 24. North America Rotavirus Infections Drug Market Size by Country in 2024
- Figure 25. North America Rotavirus Infections Drug Sales Market Share by Country (2020-2031)
- Figure 26. North America Rotavirus Infections Drug Revenue Market Share by Country (2020-2031)
- Figure 27. United States Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 28. Canada Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 29. Europe Rotavirus Infections Drug Market Size by Country in 2024
- Figure 30. Europe Rotavirus Infections Drug Sales Market Share by Country (2020-2031)
- Figure 31. Europe Rotavirus Infections Drug Revenue Market Share by Country (2020-2031)
- Figure 32. Germany Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 33. France Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 34. U.K. Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 35. Italy Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 36. Netherlands Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 37. Nordic Countries Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 38. Asia Pacific Rotavirus Infections Drug Market Size by Country in 2024
- Figure 39. Asia Pacific Rotavirus Infections Drug Sales Market Share by Country (2020-2031)
- Figure 40. Asia Pacific Rotavirus Infections Drug Revenue Market Share by Country (2020-2031)
- Figure 41. China Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 42. Japan Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 43. South Korea Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 44. India Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 45. Australia Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 46. China Taiwan Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 47. Southeast Asia Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 48. Southeast Asia Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 49. South America Rotavirus Infections Drug Market Size by Country in 2024
- Figure 50. South America Rotavirus Infections Drug Sales Market Share by Country (2020-2031)
- Figure 51. South America Rotavirus Infections Drug Revenue Market Share by Country (2020-2031)
- Figure 52. Mexico Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 53. Brazil Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 54. Argentina Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 55. Middle East and Africa Rotavirus Infections Drug Market Size by Country in 2024
- Figure 56. Middle East and Africa Rotavirus Infections Drug Sales Market Share by Country (2020-2031)
- Figure 57. Middle East and Africa Rotavirus Infections Drug Revenue Market Share by Country (2020-2031)
- Figure 58. Turkey Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 59. Saudi Arabia Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 60. UAE Rotavirus Infections Drug Revenue Growth Rate (2020-2031) & (US$ Million)
- Figure 61. Global Rotavirus Infections Drug Sales Market Share by Type (2020-2031)
- Figure 62. Global Rotavirus Infections Drug Revenue Market Share by Type (2020-2031)
- Figure 63. Global Rotavirus Infections Drug Price (US$/unit) by Type (2020-2031)
- Figure 64. Global Rotavirus Infections Drug Sales Market Share by Application (2020-2031)
- Figure 65. Global Rotavirus Infections Drug Revenue Market Share by Application (2020-2031)
- Figure 66. Global Rotavirus Infections Drug Price (US$/unit) by Application (2020-2031)
- Figure 67. Rotavirus Infections Drug Value Chain
- Figure 68. Rotavirus Infections Drug Production Mode & Process
- Figure 69. Direct Comparison with Distribution Share
- Figure 70. Distributors Profiles
- Figure 71. Rotavirus Infections Drug Industry Opportunities and Challenges
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.



